KNSY » Topics » Research and Development

This excerpt taken from the KNSY 10-K filed Sep 15, 2008.

Research and Development

Our research and development and regulatory and clinical staff consisted of 85 individuals as of August 31, 2008. Our research and development efforts are focused on the continued development of our endovascular platform and our biomaterials based products and capabilities. We incurred total research and development expenses of $17.2 million, $20.3 million and $19.0 million in fiscal 2008, 2007 and 2006, respectively, which included significant charges related to the discontinuance of the Embolic Protection Platform and the transition to our new facility. See Item 7—“Management’s Discussion and Analysis” below and the Notes to the Financial Statements included in this Form 10-K for further information.

In addition to the resources dedicated to the product development process, we have an internal regulatory affairs and clinical management staff responsible for managing our clinical trials and obtaining regulatory approvals for our products. Our regulatory department also works closely with several of our customers to obtain regulatory approvals for their products in the U.S., the European Union and several other countries.

This excerpt taken from the KNSY 10-K filed Sep 13, 2007.

Research and Development

Our research and development and regulatory and clinical staff consisted of 84 individuals as of August 31, 2007. Our research and development efforts are focused on the continued development of our endovascular platform and our biomaterials capabilities. We incurred total research and development expenses of $20.3 million, $19.0 million and $15.1 million in fiscal 2007, 2006 and 2005, respectively, which included significant charges related to the discontinuance of the Embolic Protection Platform and the transition to our new facility. See Item 7—“Management’s Discussion and Analysis” below and Notes to the Financial Statements for further information.

 

15


Table of Contents

In addition to the resources dedicated to the product development process, we have an internal regulatory affairs and clinical management staff responsible for managing our clinical trials and obtaining regulatory approvals for our products. Our regulatory department also works closely with several of our customers to obtain regulatory approvals for their products in the U.S., the European Union and several other countries.

This excerpt taken from the KNSY 10-K filed Sep 13, 2006.

Research and Development

Our research and development and regulatory and clinical staff consisted of 102 individuals as of August 24, 2006. Our research and development efforts are focused on the continued development of our endovascular platform and our biomaterials capabilities. We incurred total research and development expenses of $19.0 million, $15.1 million, and $16.4 million in fiscal 2006, 2005 and 2004, respectively.

In addition to the resources dedicated to the product development process, we have an internal regulatory affairs and clinical management staff responsible for managing our clinical trials and obtaining regulatory approvals for our products. Our staff also works closely with several of our customers to obtain regulatory approvals for their products in the U.S., the European Union and several other countries.

This excerpt taken from the KNSY 10-K filed Sep 13, 2005.

Research and Development

 

Our research and development and regulatory and clinical staff consisted of 103 individuals as of September 6, 2005. Our research and development efforts are focused on the continued development of the TriActiv System and our biomaterials capabilities. We incurred total research and development expenses of $15.1 million, $16.4 million, and $14.5 million in fiscal 2005, 2004 and 2003, respectively.

 

In addition to the resources dedicated to the product development process, we have an internal regulatory affairs and clinical management staff responsible for managing our clinical trials and obtaining regulatory approvals for our products. Our staff also works closely with several of our customers to obtain regulatory approvals for their products in the U.S., the European Union and several other countries.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki